BRCA1 has been reported to have roles in DNA damage repair, cell cycle checkpoint control, transcriptional regulation and ubiquitination. We have previously demonstrated that BRCA1 is a potent activator of a subset of interferon (IFN)-regulated genes and that BRCA1 synergistically activated a number of these genes in the presence of IFN-c, but not type I IFNs. Here we report that one of these targets, 2,5 oligoadenylate synthetase (2,5 OAS), is a mediator of BRCA1/IFN-c-induced apoptosis. We show that the induction of 2,5 OAS in response to IFN-c is BRCA1 and STAT1 dependent. Consistent with a role as a negative regulator of proliferation, transient transfection of 2,5 OAS into breast cancer cell lines results in decreased colony growth and apoptosis. Furthermore we show that IFN-c-induced apoptosis is dependent on functional BRCA1 and STAT1 and we demonstrate that IFN-c-induced apoptosis is dependent on 2,5 OAS induction. 2,5 OAS is the only known upstream regulator of RNaseL, a recently identified hereditary prostate tumour suppressor gene implicated in apoptosis. We propose that BRCA1 may be an upstream regulator of RNaseL, acting in concert with IFN-c to transcriptionally activate 2,5 OAS, leading to the downstream activation of RNaseL and apoptosis.
Introduction
BRCA1 encodes a tumour suppressor gene that is mutated in the germ line of women with a genetic predisposition to breast and ovarian cancer (Miki et al., 1994) . Although the exact function of BRCA1 remains to be defined, roles in DNA damage repair, cell cycle checkpoint control, transcriptional regulation and more recently ubiquitination have been inferred (Hashizume et al., 2001) . A large body of evidence exists to suggest a role for BRCA1 in transcriptional regulation (Harkin et al., 1999) . BRCA1 copurifies with the RNA polymerase II holoenzyme complex through an association with RNA helicase A (Anderson et al., 1998) , suggesting that BRCA1 is a component of the core transcriptional machinery. BRCA1 has also been shown to associate with a range of different transcription factors including p53 (Ouchi et al., 1998) , c-Myc (Li et al., 2002) , ATF1 (Houvras et al., 2000) and STAT1 (Ouchi et al., 2000) , modulating their activity. These findings suggest that BRCA1 functions as either a coactivator or corepressor of transcription, an effect that may involve its ability to recruit both the basal transcription machinery and proteins implicated in chromatin remodelling including the histone deacetylases HDAC1 and 2 (Yarden and Brody, 1999) and the SWI/SNF-related chromatin-remodelling complex (Bochar et al., 2000) . We have previously identified a number of novel BRCA1 target genes including GADD45 (Harkin et al., 1999) and more recently have defined a subset of interferon (IFN)-inducible genes that are also regulated by BRCA1. We observed a synergistic induction of a subset of these genes when breast cancer cells were induced to express BRCA1 in the presence of IFN-g, but not IFN-a or IFN-b (Andrews et al., 2002) . Consistent with these observations, BRCA1 has been reported to bind to and function as a coactivator for STAT1, the major effector of the IFN-g signalling pathway, thereby providing a mechanistic basis for our observations (Ouchi et al., 2000) .
A number of studies have also explored the role played by BRCA1 as a regulator of apoptosis. It was reported that exogenous expression of BRCA1 induced apoptosis, an effect that was dependent on c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), and which correlated with the induction of GADD45 (Harkin et al., 1999) . Subsequently, it was shown that BRCA1 induced apoptosis through a pathway that involves MEKK4, H-ras, Fas, Fas ligand and the activation of caspase-9 (Takekawa and Saito, 1998; Thangaraju et al., 2000) . We have previously demonstrated that BRCA1 sensitizes breast cancer cells to apoptosis induced by IFN-g (Andrews et al., 2002) and to the spindle poison paclitaxel (Mullan et al., 2001; Gilmore et al., 2004) . However, it has also been reported that BRCA1 induces resistance to DNA-damaging agents (Bhattacharyya et al., 2000; Lee et al., 2000; Moynahan et al., 2001) and that BRCA1 specifically redirects the p53 DNA damage response pathway towards cell cycle arrest rather than apoptosis (Mac Lachlan et al., 2002) . In order to address this further, we examined the role played by BRCA1 in mediating the cellular response to a range of different DNA-damaging and antimicrotubule agents. We demonstrated that BRCA1 is a differential modulator of chemotherapyinduced apoptosis mediating resistance to a range of DNA-damaging agents including etoposide and cisplatin while sensitizing breast cancer cells to apoptosis induced by the antimicrotubule agents paclitaxel and vinorelbine (Quinn et al., 2003) . A number of clinical studies have since confirmed these findings and suggest that BRCA1-deficient tumours may respond well to DNA damage-based chemotherapy . Hence, dependent on the nature of the cellular stress, it appears that BRCA1 can regulate both proand antiapoptotic pathways.
The 2,5 oligoadenylate synthetase (OAS) system is an IFN-induced antiviral pathway, which confers protective and antiproliferative properties. When activated, OAS proteins catalyse the polymerization of ATP into 2 0 -5 0 -linked oligomers, leading in turn to the activation of a latent endogenous endoribonuclease called RNaseL. Activated RNaseL cleaves both cellular and viral mRNA resulting in ribotoxic stress, JNK activation and apoptosis. RNaseL has been reported to be a potent inducer of apoptosis, and transfection of a dominantnegative RNaseL into several cell lines has been shown to block apoptosis (Castelli et al., 1998) . Furthermore, RNaseL-negative mice display an impaired IFN response pathway and cells derived from RNaseL knockout mice demonstrated substantial suppression of apoptosis following treatment with a number of apoptotic agents (Zhou et al., 1997) . Recently, it has been demonstrated that RNaseL (also known as hereditary prostate cancer 1 (HPC1) or prostate cancer 1 (PRCA1)), is mutated in a number of hereditary prostate cancer families and segregates with disease Rokman et al., 2002; Silverman, 2003) . Finally, an RNaseL founder mutation (471de-lAAAG) has been shown to be associated with prostate cancer in Ashkenazi Jews, a population commonly segregating with familial breast and ovarian cancers due to founder BRCA1 and BRCA2 mutations (Rennert et al., 2002) .
In this study, we show that 2,5 OAS induction is dependent on functional BRCA1 and that 2,5 OAS is synergistically induced by BRCA1 and IFN-g resulting in apoptosis. Since RNaseL has been identified as a hereditary prostate cancer gene and a described regulator of apoptosis, our findings raise the intriguing possibility that the 2,5 OAS/RNaseL pathway may represent a novel apoptotic mechanism through which BRCA1 may regulate cellular fate in breast, ovarian and prostate tissue.
Results

2,5 OAS is synergistically induced by BRCA1 and IFN-g
We previously identified a number of IFN-inducible genes as potential BRCA1 targets by microarray-based expression profiling. One of these targets, 2,5 OAS, was of particular interest since it has previously been implicated in viral-induced apoptosis (Castelli et al., 1998) , and as the activator of a novel hereditary prostate cancer tumour suppressor gene, RNaseL . Northern blot analysis confirmed that 2,5 OAS mRNA expression levels increased following inducible expression of exogenous BRCA1 ( Figure 1a ) and furthermore demonstrated that 2,5 OAS mRNA was synergistically increased following inducible expression of BRCA1 in the presence of IFN-g ( Figure 1a ). In order to define the requirement for BRCA1 and the specificity for IFN-g, we evaluated the expression level of 2,5 OAS in the BRCA1-deficient HCC1937 cells transfected with an empty vector or reconstituted with wild-type exogenous BRCA1 following treatment with IFN-a, IFN-b or IFN-g. Northern blot analysis demonstrated that 2,5 OAS expression was dramatically enhanced in the BRCA1-reconstituted cells following treatment with IFN-g but not IFN-a or IFN-b (Figure 1b) . In order to confirm the requirement for BRCA1, by an alternative approach we inhibited endogenous BRCA1 in the T47D breast cancer cell line using a BRCA1-specific siRNA approach and evaluated the ability of IFN-g to induce expression of 2,5 OAS. Western blot analysis confirmed inhibition of endogenous BRCA1 48 h following transfection with a BRCA1-specific siRNA compared to scrambled oligo controls (Figure 1c, top panel) . Consistent with the results described above, siRNA-mediated inhibition of endogenous BRCA1 significantly abrogated IFN-g-mediated induction of 2,5 OAS, suggesting that BRCA1 plays an important role in the regulation of this pathway. Since 2,5 OAS has been reported to function as an upstream activator of RNaseL, we wished to determine if BRCA1 modulates RNaseL activity. In order to do this, we adopted a dual approach. In the first instance, we examined the amount of degradation of rRNA following incubation with protein lysates from BRCA1-reconstituted HCC-BR cells compared to the BRCA1-deficient HCC-empty vector (HCC-EV) controls. Reconstitution of BRCA1 results in enhanced degradation of rRNA consistent with RNaseL activation (Figure 1d ). In order to more specifically measure the effect of BRCA1 on RNaseL activity, we developed a specific radiolabelled RNaseL assay. This assay made use of a radiolabelled RNA oligonucleotide, C 11 UUC 7 , containing a consensus RNaseL cleavage site. Incubation of this substrate with lysates from BRCA1-deficient or -reconstituted cells demonstrated enhanced cleavage of substrate when functional BRCA1 was present (Figure 1e ). Together, these data suggest a role for BRCA1 in mediating RNaseL activity. . Cells were transfected with either scrambled or BRCA1-specific siRNA oligonucleotides and left untreated or treated with 100 U/ml IFN-g for 24 h. GAPDH was used as a loading control (lower panel). (d) rRNA degradation assay demonstrating enhanced BRCA1-mediated degradation of rRNA. Ethidium bromide staining of an agarose gel following incubation of total RNA with protein extracts prepared from HCC-EV and HCC-BR cells that had been left untreated (C) or treated with 100 U/ml IFN-g for 1, 3 or 6 h. NL (no lysate control) shows rRNA that had been incubated in buffer without protein lysate. (e) Radiolabelled RNaseL activity assay demonstrating enhanced BRCA1-mediated cleavage of an RNaseL-specific substrate. A single-stranded RNA probe (C 11 UUC 7 ) was end-labelled with [ 32 P]ATP and incubated with protein lysates prepared from HCC-EV and HCC-BR cells that had been left untreated (C) or treated with 100 U/ml IFN-g for 1, 3 or 6 h. Autoradiography revealed enhanced cleavage of the radiolabelled probe following incubation with lysates from BRCA1-reconstituted HCC-BR cells. NL (no lysate control) represents labelled oligonucleotide that had been incubated in buffer without protein lysate. Lysates from BRCA1 identical aliquots were used as a substrate in RNaseL assays. The cell lysates and reaction conditions are the same as in (d). After incubations, the reactions were run on an acrylamide gel followed by autoradiography BRCA1 regulates 2,5 OAS/RNaseL PB Mullan et al
IFN-g-mediated induction of 2,5 OAS requires functional STAT1 and BRCA1
Since STAT1 is a critical component of the IFN-g signalling pathway and has been reported to interact with BRCA1, we evaluated its role in IFN-g-and BRCA1-mediated induction of 2,5 OAS. In order to do this, we initially used an siRNA approach to inactivate endogenous STAT1 in the T47D breast cancer cell line. Western blot analysis confirmed siRNA-mediated inhibition of endogenous STAT1 in both unstimulated cells and cells stimulated with IFN-g ( Figure 2a ). IFN-g treatment of T47D cells, which had been transfected with a scrambled control oligonucleotide, resulted in a significant induction of 2,5 OAS mRNA expression ( Figure 
IFN-g-mediated apoptosis is BRCA1 and STAT1 dependent
Having defined a requirement for BRCA1 and STAT1 in mediating IFN-g induction of 2,5 OAS, we also wished to determine if BRCA1 and STAT1 were required for IFN-g-mediated apoptosis. In order to evaluate this, we compared the ability of IFN-g to induce apoptosis in the BRCA1-deficient HCC-EV cells compared to the BRCA1-reconstituted HCC-BR cells (Figure 3a) . Western blot analysis confirmed expression of exogenous BRCA1 in the HCC-BR cells (Figure 3a(i) ). Consistent with a role for BRCA1 in mediating IFN-g-induced apoptosis, IFN-g treatment of the HCC-BR cells resulted in enhanced levels of cleaved caspase-3 compared to HCC-EV cells (Figure 3a (ii)).
To validate this, in a second cell line model system we evaluated the ability of IFN-g to induce apoptosis in T47D cells following inhibition of endogenous BRCA1. Western blot analysis confirmed siRNA-mediated inhibition of BRCA1 in these cells (Figure 3b(i) ). Consistent with the previous data, siRNA-mediated inhibition of endogenous BRCA1 in the T47D cells abrogated IFN-g-mediated apoptosis, as evidenced by a marked reduction in cleaved caspase-3 levels (Figure 3b (ii)). Using a similar approach, we evaluated if STAT1 was required for IFN-g-mediated apoptosis using a STAT1-specific siRNA approach. Western blot analysis confirmed inhibition of endogenous STAT1 in T47D cells (Figure 3c , top panel). siRNA-mediated inhibition of endogenous STAT1 significantly inhibited IFN-ginduced apoptosis, as measured by a specific reduction in cleaved caspase-3 levels ( Figure 3c , middle panel). To confirm that the enhanced level of IFN-g-induced apoptosis observed in the BRCA1-reconstituted HCC-BR cells (Figure 3a ) was also dependent on functional STAT1, we repeated these experiments in the HCC-EV and HCC-BR cells. Inhibition of endogenous STAT1 
2,5 OAS mediates IFN-g-induced apoptosis
As discussed earlier, the 2,5 OAS/RNaseL pathway has been previously implicated in the induction of apoptosis following viral infection. We therefore postulated that BRCA1 and IFN-g may cooperate in normal cell growth to elicit apoptosis via the 2,5 OAS/RNaseL pathway. In order to investigate this further, we generated a 2,5 OAS-V5 fusion construct and transiently transfected it into a number of breast cancer cell lines. Western blot analysis using an antibody directed against the V5 tag confirmed expression of exogenous 2,5 OAS in these cells (Figure 4a ). In order to determine the consequence of 2,5 OAS expression on cellular proliferation, we carried out colony count assays in the T47D and MCF-7 cell lines following transfection with 2,5 OAS-V5 or an empty vector as a control. Transfection of both the T47D and MCF-7 cells with 2,5 OAS-V5 expression constructs resulted in a significantly reduced colony number compared to empty vector-transfected controls ( Figure 4b ). The percentage growth inhibition mediated by 2,5 OAS was calculated at greater than 75% for the T47D cells and 60% for the MCF-7 cells (Figure 4c ). The V5-tagged 2,5 OAS was as potent as the native protein in inhibiting clonogenicity and allowed us to detect exogenous 2,5 OAS as there was no suitable commercial 2,5 OAS antibody available. To determine if the observed reduction in the number of colonies reflected the induction of apoptosis in these cells, we (ii) Caspase-3 cleavage assays demonstrating the requirement for BRCA1 in IFN-g-induced apoptosis. T47D cells were transfected with a scrambled control siRNA or BRCA1-specific siRNA and left untreated or treated with 100 U/ml IFN-g for 24 h. Western blotting was performed for BRCA1 (top panel) and caspase-3 cleavage products (middle panel). The identical lysates were reprobed with a GAPDH antibody as a loading control (lower panel). (c) Caspase-3 cleavage assays demonstrating the requirement for STAT1 in IFN-g-induced apoptosis. T47D cells were transfected with a scrambled control oligo or a STAT1-specific siRNA oligo, and treated with 100 U/ml IFN-g or with 300 U/ml IFN-g for 24 h. Western blotting was performed for STAT1 (top panel) and caspase-3 cleavage products (middle panel). The identical lysates were reprobed with a GAPDH antibody as a loading control (lower panel). (d) Caspase-3 cleavage assays demonstrating the requirement for both STAT1 and BRCA1 in IFN-g-induced apoptosis. HCC-EV cells and HCC-BR cells were transfected with a scrambled control oligo or a STAT1-specific siRNA oligo and treated with 100 U/ml IFN-g or 300 U/ml IFN-g. Western blotting was performed for STAT1 (top panel) and caspase-3 cleavage products (middle panel). The identical lysates were reprobed for GAPDH protein as a loading control (lower panel)
BRCA1 regulates 2,5 OAS/RNaseL PB Mullan et al carried out caspase-3 and PARP cleavage assays. Enhanced caspase-3 cleavage was observed in T47D cells ( Figure 4d ) and similarly enhanced cleavage of PARP was observed in MCF-7 cells (Figure 4e ), following transient expression of 2,5 OAS-V5 compared to vector-transfected controls, suggesting that these cells were undergoing apoptosis. To examine if 2,5 OAS induction was required for IFN-g-mediated apoptosis, we inhibited endogenous 2,5 OAS using an siRNA approach and evaluated the effect on IFN-g-induced apoptosis (Figure 5a ). Inhibition of endogenous 2,5 OAS expression following IFN-g treatment (100 and 300 U/ml) was confirmed by Northern blot analysis (Figure 5a ). Consistent with a role for 2,5 OAS in mediating IFN-g-induced apoptosis, inhibition of endogenous 2,5 OAS significantly abrogated IFN-ginduced caspase-3 cleavage in T47D cells compared to cells transfected with a scrambled control oligonucleotide (Figure 5a ). 2,5 OAS siRNA also totally inhibited the antiproliferative effects of IFN-g in cell growth experiments (Figure 5b ). These data suggest that 2,5 OAS represents a potential effector of IFN-g/BRCA1/ STAT1-mediated apoptosis.
Discussion
In this study, we demonstrate the synergistic induction of 2,5 OAS by BRCA1 in the presence of IFN-g. We had previously shown that inducible expression of BRCA1 in the presence of IFN-g resulted in the induction of apoptosis, whereas this was not the case with the type I IFNs (Andrews et al., 2002) . Here we provide evidence to suggest that BRCA1 is required for this process, since BRCA1 mutant cells were deficient for both 2,5 OAS induction and caspase-3 cleavage following IFN-g treatment (both of which were restored with BRCA1 reconstitution). Inhibition of endogenous BRCA1 and STAT1 prevented IFN-g-mediated induction of 2,5 OAS and apoptosis, demonstrating their importance in this cell death pathway. Consistent with this finding, exogenous expression of 2,5 OAS induced apoptosis, while 2,5 OAS siRNA inhibited apoptosis in response to IFN-g. These observations suggest a role for the 2,5 OAS pathway in BRCA1/IFN-g-mediated apoptosis. The ability of BRCA1 to act as a transcriptional coactivator (in particular with STAT1) and stimulate the transcription of IFN target genes represents yet another interesting facet of the diverse functions associated with BRCA1. Evidence to support a role for BRCA1 in the regulation of the IFN-g signalling pathway has previously been documented. It was initially demonstrated that BRCA1 could interact with STAT1 and regulate its transcriptional activity (Ouchi et al., 2000; Andrews et al., 2002) . In the context of breast cancer biology, it has also been demonstrated that RAG2 and STAT1/IFN-gR-deficient mice exhibit a specific susceptibility to spontaneous mammary gland carcinomas, suggesting that lymphocytes and IFN-g cooperate to protect against these tumours (Shankaran et al., 2001) . The current study suggests a pathway through which BRCA1 and IFN-g cooperate to mediate apoptosis through the induction of 2,5 OAS. The fact that RNaseL is wholly dependent on 2,5 OAS for activation suggests that RNaseL activation may represent a key target of this pathway. Consistent with this hypothesis, we have demonstrated enhanced RNaseL activity following reconstitution of exogenous BRCA1 into the BRCA1 mutant HCC1937 cells.
It is unlikely that 2,5 OAS is the sole mediator of BRCA1-and IFN-g-induced apoptosis, although our data suggest that it represents a key component of this pathway. To investigate if the growth suppressive function of BRCA1 and IFN-g was exclusively occurring through an apoptotic pathway, we also carried out a series of cell cycle experiments following treatment with IFN-g in the presence or absence of BRCA1. We failed to detect any major perturbations in cell cycle profiles to indicate activation of a cell cycle checkpoint, suggesting that the main pathway activated was a cell death pathway.
The 2,5 OAS/RNaseL system has also been linked to growth control in hormonally responsive cell types including, for example, oestrogen withdrawal (Stark et al., 1979) , the cessation of mammary gland lactation and tamoxifen treatment of oestrogen receptor-positive breast cancer cells (Agrawal et al., 2002) . In addition, the induction of 2,5 OAS protein has also been reported following treatment with the antimicrotubule agent paclitaxel (Moos and Fitzpatrick, 1998). Since our group has previously shown that BRCA1 sensitizes breast cancer cells to paclitaxel-mediated apoptosis, this provides a potential mechanism through which BRCA1 may regulate apoptosis at the mitotic checkpoint following microtubule damage. A recent microarray screen comparing a parental nontumorigenic benign prostatic hyperplastic (BPH) cell line with a tumorigenic derivative showed that a significant portion of downregulated genes in the tumorigenic cell line were IFNinducible genes (Shou et al., 2002) . 2,5 OAS was the second highest downregulated gene in both independent tumorigenic clones analysed. In addition, specific IFNinducible genes including 2,5 OAS were shown to be downregulated in approximately 30% of 49 clinically characterized prostatic adenocarcinoma samples, providing further evidence to suggest a protective role for the IFN system, and in particular 2,5 OAS, in growth control.
One of the major issues to be addressed in the future relates to the exact mechanism through which BRCA1 and IFN-g synergize to regulate expression of 2,5 OAS and induce apoptosis. Classically, type I IFNs (predominantly IFN-a and IFN-b) activate target genes through the ISGF3 transcription factor complex consisting of STAT1, STAT2 and p48, which primarily binds to promoters containing ISGF3 elements. Type II IFN (IFN-g) classically activates the GAF transcription factor (STAT1 homodimers), which in turn recognizes GAS promoter elements. However, most of the genes synergistically induced by BRCA1 and IFN-g such as 2,5 OAS possess ISRE promoter elements, not GAS elements, suggesting an indirect mechanism of activation that is dependent on BRCA1 and STAT1. The inability of type I IFNs to synergistically induce 2,5 OAS and elicit apoptosis in a BRCA1-dependent manner suggests a model where BRCA1 through its ability to interact with STAT1 may regulate the OAS in IFN-g-induced apoptosis. T47D cells were transfected with a scrambled control siRNA oligo or a 2,5 OAS-specific oligo and treated with 100 U/ml IFN-g or 300 U/ml IFN-g. Northern blotting analysis was performed for 2,5 OAS (top panel) and for GAPDH cDNA as a loading control (second panel). Protein lysates were prepared from the same experiment and Western blotting analysis performed for caspase-3 cleavage (third panel) and the identical lysates were probed for GAPDH as loading control (lower panel).
(b) Histogram representing three independent cell count experiments demonstrating that 2,5 OAS is required for IFN-g-induced apoptosis. T47D cells were transfected with a scrambled control oligo or a 2,5 OAS-specific siRNA oligo, left untreated or treated with 300 U/ml IFN-g for 24 h and cell counts performed expression of type I IFNs and IFN receptors, which possess GAS promoter elements. The autocrine secretion of IFNs -a and IFN-b in such a model may activate the type I pathway and in turn activate the ISFG3 transcription factor complex leading to the induction of genes such as 2,5 OAS. So, in addition to regulating conventional growth suppressor pathways in response to DNA damage, tumour suppressor genes such as BRCA1 may also be utilized to regulate an immunosurveillance pathway that functions in parallel to suppress tumour formation. Consequently, inactivation of BRCA1 in breast epithelial cells may disrupt the natural tumour suppressor function of the immune system leading to tumour formation.
Materials and methods
Generation of cell lines
MBR62-bcl2, HCC-EV and HCC-BR were maintained as described previously (Mullan et al., 2001; Quinn et al., 2003) .
The MBR62-bcl2 cell line was generated first from the MDA435 parental breast line by stably expressing the tetracycline VP-16 transactivator plasmid to generate the MDA47 founder cell line; MDA47 founder cells were used to generate stably transfected clones with tightly regulated expression of full-length wild-type BRCA1 resulting in the MBR62 cell line. A CMV-driven bcl2 expression construct was cotransfected with a hygromycin resistance plasmid to give constitutive expression of bcl2 (MBR62-bcl2).
HCC1937 cells were originally established from a primary breast carcinoma homozygous for the BRCA1 5382insC mutation. HCC-EV and HCC-BR cell lines were generated by transfection of HCC1937 cells with either an empty RcCMV expression plasmid or RcCMV containing full-length wild-type BRCA1, respectively.
siRNA experiments
The target sequences for BRCA1 (ArraDx-BRCA1), STAT1 (ArraDx-STAT1) and 2,5 OAS (ArraDx-OAS) siRNA oligos were designed by ArraDx, Ltd, Craigavon, Co. Armagh, Northern Ireland BT63 (www.arradx.com). Scrambled oligos were designed for each of the above sequences. siRNA oligonucleotides were mixed with Oligofectamine (Invitrogen) in Optimem1 (Invitrogen) at a final concentration of 200 nM and left for 30 min with occasional shaking (according to the manufacturer's instructions). Cells were washed once in phosphate-buffered saline (PBS) to remove traces of serum and transfections were added to cell monolayers and left for 4-8 h. Then, transfections were supplemented with medium containing 30% serum and left for 24 h. This process was repeated the next day. IFN-g was applied 48 h after the second transfection.
Colony count assays
Colony count assays were performed in six-well dishes (NUNCLON) using lipofectin-(Invitrogen) based transfection of T47D and MCF-7 breast cancer cells with mammalian expression constructs encoding 2,5 OAS. Cells were transfected with the empty vector pcDNA3.1-V5-His-TOPO (Invitrogen) as a control. Transfected clones were grown in 0.5 mg/ml G418 for 3 weeks to allow for the selection of transfected clones. Colonies were then fixed with methanol for 10 min and stained with 0.5% crystal violet (BDH Chemicals) for a further 10 min. Following several water washes, plates were allowed to air-dry before the crystal violet dye was readsorbed from the fixed cells using a sodium citrate solution and absorbance read at 540 nm. Values were expressed as percentage of transfected controls.
Northern blot analysis
RNA was isolated from cells using RNA STAT-60 Total RNA Isolation Reagent (Tel-Test Inc.) . Total RNA (20 mg) was separated on a formaldehyde gel and transferred onto Hybond-N membrane (Amersham Biosciences). cDNA probes for BRCA1 and GAPDH were prepared by RT-PCR. Probes for STAT1 and 2,5 OAS were generated by restriction enzyme digest of IMAGE clones obtained from the HGMP-Resource Centre (Hinxton, Cambridge, England). All were radiolabelled using 32 P-labelled CTP (DU-PONT) by the random primer method (Megaprime kit, Amersham Biosciences). Following purification from unincorporated label through YM-30 filters (Microcon), probes were hybridized with membranes overnight following the Church's protocol (7% SDS, 0.25 M disodium hydrogen phosphate) at 651C.
Apoptotic assays
Apoptotic assays were carried out 24 h following IFN-g treatment (usually 100 U/ml IFN-g unless otherwise indicated). Cells were washed in PBS and protein lysates were extracted in RIPA buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 0.1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS) containing a protease inhibitor cocktail (Boehringer Mannheim). Protein concentrations were measured using Bio-Rad protein assay reagent and 60 mg protein was loaded per well, separated on a 15% SDS-polyacrylamide gel and transferred to PVDF membrane (Amersham) followed by immunoblotting using an anti-caspase-3 antibody that specifically recognizes the cleaved 17 and 19 kDa caspase-3 products. For PARP cleavage assays, proteins were separated using a 12% gel and membranes probed with anti-PARP antibody that recognized the fulllength (116 kDa) and cleaved (84 kDa) PARP proteins.
Antibodies and Western blot analysis
The BRCA1 antibodies used were the mouse monoclonals Ab-1 for immunoprecipitation and Ab-4 for immunoblotting (both from Oncogene). STAT1 antibody was purchased from Cell Signalling (cat. no. 9172). PARP was detected using a mouse monoclonal antibody (BD Bioscience, cat. no. 556494). Cleaved caspase-3 was detected using the rabbit polyclonal cleaved caspase-3 (Asp 175) antibody (Cell Signaling). Mouse monoclonal anti-b-tubulin (Sigma, cat. no. T4026) and mouse monoclonal anti-GAPDH (Biogenesis, were used to ensure equal loading of protein. For BRCA1 immunoprecipitation, cells were lysed in EDTA lysis buffer (ELB; 0.25 M NaCl, 0.1% IEPGAL, 0.25 M HEPES, 5 mM EDTA, 0.5 mM DTT) containing protease inhibitor cocktail (PI). Protein lysates (1 mg) were incubated overnight at 41C with Protein-G-coupled sepharose beads (Cancer Research UK) that had been pre-annealed with Ab-1 antibody.
Immunoprecipitates were run on a 6% SDS-polyacrylamide gel.
rRNA degradation assay
Cells were washed once in PBS, scraped into a minimal volume of ice-cold PBS and pelleted at 1000 r.p.m. for 5 min. Pellets were stored at À701C until required. Pellets were then lysed in approximately 1.5 times pellet volume of cold NP-40 lysis buffer (10 mM HEPES pH 7.5; 90 mM potassium chloride; 1 mM magnesium acetate; 2 mM 2-mercaptoethanol and 100 mg/ml leupeptin (both added fresh)). After 5 min on ice, the lysate was centrifuged at 10 000 g at 41C for 10 min. The supernatant was transferred to a fresh tube and protein concentration assayed (Bio-Rad). Each 20 ml reaction consisted of 2 ml of 10 Â cleavage buffer (100 mM HEPES; 1 M potassium chloride; 50 mM magnesium acetate; 10 mM ATP and 0.14 M 2-mercaptoethanol (added fresh); 5 mg total RNA made from ZR75/1 breast cancer cells to act as a substrate; protein lysate from HCC-EV or HCC-BR cells; all made up to a final volume of 20 ml. Reactions were incubated at 301C for 30 min. RNA loading dye was then added and samples were then run on 1.8% agarose gels and stained with ethidium bromide.
Radiolabelled RNaseL substrate assay
Cells were washed once in PBS, scraped into a minimal volume of ice-cold PBS and pelleted at 1000 r.p.m. for 5 min. Pellets were stored at À701C until required. Pellets were then lysed in approximately 1.5 times pellet volume of cold NP-40 lysis buffer (10 mM HEPES pH 7.5; 90 mM potassium chloride; 1 mM magnesium acetate; 2 mM 2-mercaptoethanol and 100 mg/ml leupeptin (both added fresh)). After 5 min on ice, the lysate was centrifuged at 10 000 g at 41C for 10 min. The supernatant was transferred to a fresh tube and protein concentration assayed (Bio-Rad). A 100 nM portion of the synthetic oligoribonucleotide C 11 UUC 7 was end-labelled with [ 32 P]ATP using T4-Polynucleotide Kinase (NEB). It was then purified using YM-30 filters with two washes of TE and eluted with 20 ml of H 2 O. A 1 mg portion of protein lysate was incubated with 1 ml of labelled probe in 30 ml 1 Â cleavage buffer for 30 min. Electrophoresis was performed on a 20% acrylamide/7 M urea/TBE gel followed by autoradiography. Aliquots of each protein sample were subjected to Western blotting and probed for GAPDH to ensure equal amounts of protein were used in RNaseL assay samples.
